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Personalized medicine is increasingly being employed across many areas of clinical practice, as genes associated with
specific diseases are discovered and targeted therapies are developed. Mobile apps are also beginning to be used in
medicine with the aim of providing a personalized approach to disease management. In some areas of medicine,
patient-tailored risk prediction and treatment are applied routinely in the clinic, whereas in other fields, more work is
required to translate scientific advances into individualized treatment. In this forum article, we asked specialists in
oncology, neurology, endocrinology and mobile health technology to discuss where we are in terms of personalized
medicine, and address their visions for the future and the challenges that remain in their respective fields.
Keywords: Diabetes, Genetics, Mobile health, Oncology, Personalized medicine, Smartphone, Stroke, Targeted therapyProgress and challenges in individualizing cancer
treatment
Daniel F Hayes
Oncology is an area that I believe has the greatest po-
tential for the personalization of medicine, but probably
has had the least application until recently. Over the last
40 or 50 years, especially in medical oncology, we have
taken a ‘one size fits all’ approach; our only efforts at
personalization have been trying to tailor specific che-
motherapies based on the tissue of origin. For example,
we treat breast cancer with slightly different drugs than
we treat lung cancer. Frankly, these distinctions are not
very great. The only other effort to individualize treatment
is to give the chemotherapy based on the height and weight
of the individual patient - so we try to get the dose approxi-
mately right. In both cases, we almost certainly overtreat
many patients, give treatments that are not going to work,
and under- or overdose patients. So there is a lot of room
to improve treatments in medical oncology.
The reason I believe medical oncology has the greatest
potential for personalized medicine is, because unlike many
other diseases, we have fairly easy access to the somatic
tissue that we are trying to address. For example, the* Correspondence: bmcmedicineeditorial@biomedcentral.com
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2014cardiologist cannot carry out heart biopsies very easily.
The general internists who are treating hypertension
have put efforts into individualized treatment based on
inherited genetic single nucleotide polymorphisms but,
so far, that field has not advanced very far. In cancer,
on the other hand, we have access to the tumor and we
can look for various things the cancer is doing that is
different from normal tissue and try to focus on that.
The result of these studies over the last few years has
been so-called targeted therapy.
In fact, my earlier cynical comments notwithstanding,
targeted therapy has been used in oncology for the last 120
years or so, starting with Sir George Beatson, who was a
Scottish physician and surgeon. He raised dairy goats and
pioneered the hypothesis that there might be some connec-
tion between the ovaries and the breasts. He removed the
ovaries from three women with breast cancer and reported
that two of them had what we would now call a response.
Beatson was removing the growth factor estrogen from tis-
sue expressing the estrogen receptor that needed estrogen to
grow [1]. It took 60 or 70 years to learn the molecular biol-
ogy behind Beatson’s observation that has allowed us to, for
example, focus endocrine therapy on people who are likely
to benefit from it, that is, those whose cancer is estrogen
receptor-positive. Endocrine therapy is not given to people
who are not likely to benefit (estrogen receptor-negative).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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offer more personalized treatment targeting the HER2
molecule; there are now many therapies, starting with
trastuzumab, directed against HER2 [2]. I think the suc-
cess with HER2-targeted therapies in breast cancer has
now led to progress in a number of other diseases. For ex-
ample, in chronic myelogenous leukemia, the transloca-
tion of the so-called ‘Philadelphia chromosome’ is well
known, the microbiology behind it is fully understood,
and we now have many drugs - starting with gefitinib -
against it, which have been quite successful [3]. So I think
the door of targeted personalized therapies is just starting
to open and the floodgates will open in the next few years.
There are some obstacles associated with introducing
so-called “personalized medicine” into oncology. The
concern we have is really threefold. Firstly, we have to be
certain that the individual test or biomarker for studying
is accurate, reproducible and reliable. Whereas drugs are
very carefully controlled, either by the US Food and Drug
Administration or by various regulatory bodies, there is
no similar regulatory oversight for tumor biomarker tests.
Many tests that have been developed are not necessarily
vetted analytically, and so it is not clear whether you
can depend on them. Some tests are analytically validated
independently, but many are not.The second obstacle is that the clinical data that have
been generated are often from what we call ‘studies of
convenience’; somebody has some samples and someone
else has an assay, and results are generated without
really addressing what the question was to begin with.
As a doctor and as a patient, it is not enough to know
that a marker separates one population into two with
statistical significance; the important question is whether
the marker does it in a way that is important clinically.
It is essential to know whether I would withhold therapy
from one patient or give therapy to another patient because
the results have shown that those patients are separate
and that giving the therapy or withholding it improves
their outcomes. We call that ‘clinical utility’. There are
actually precious few tumor biomarker tests that have
demonstrated both analytical validity and clinical utility.
We are trying to encourage researchers to approach tumor
biomarker tests in the same way that we approach drugs so
that we can hasten introduction of these tests into the clinic
because there will be a better set of ground rules.
The genomics revolution has great potential in the
development of personalized oncology; I think it will
revolutionize us in two ways. Firstly, there are already tests
based on so-called ‘signatures of expression’, particularly
with expression of RNA. For example, you can put 10,000
genes into the mix and come up with a genomic signature
that can predict a patient’s outcome. This approach also
has limitations; it is not yet good enough. We really need a
signature that can guide treatment decisions.
Indeed, there have been very few assays that have
come out of the genomics revolution in the last 12 years.
One of the most highly proven and adopted is the ‘21 gene
recurrence score’ for breast cancer [4]. There is really good
evidence to show that if an estrogen receptor-positive
node-negative patient has a low recurrence score, her odds
of the cancer recurring over the next 10 years - assuming
she will get endocrine therapy - are so low that even if
chemotherapy works, it will not help enough people to
outweigh the potentially life-threatening side effects of
chemotherapy. This assay is widely used in the US and
we have seen an approximately 20% reduction in the use
of chemotherapy for that group of patients over the last
10 years [5]. In my opinion, this is exactly what we are
trying to do with patient-tailored therapy.
The next step is next-generation sequencing, the abil-
ity to sequence the genome of an entire tumor and then
compare what is found in the tumor to what is found in
the patient’s normal germ line DNA. The aim is to find
mutations or copy number variations, amplifications or
deletions. We can look for changes for which we either
already know that there are drugs that work, or place
the patient on trials that have drugs that are directed to-
wards that specific change. Next-generation sequencing
is really in its infancy; it is a year or two old. Sequencing
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there are many studies being generated in which pa-
tients’ cancers are being biopsied, fully sequenced in one
way or another, and then compared to their germ line
DNA to see whether or not that patient might be more
specifically treated. There are caveats to this approach.
A major concern is how accurate these assays are ana-
lytically. Just like any test, mistakes can be made in gen-
ome sequencing. Moreover, these methods will detect
genetic abnormalities that may or may not actually have
biological or, more importantly, clinical significance. The
second caveat is whether or not there are context-specific
responses to our drugs. In other words, a mutation in, say,
HER2 may be important for drug X in breast cancer, but
that same mutation in lung cancer may not have the same
biology because there are tissue-specific factors at play.
Looking into the future of personalized oncology
I have three visions. The first is something we call the
‘vicious cycle of tumor biomarker generation’. The vicious
cycle involves an inconsistent regulatory environment that
has confused people as to how they should develop new
tests, as well as insufficient reimbursement for a bio-
marker test [6]. I believe that the people who design and
develop tumor biomarker tests should be in line for the
kind of reimbursements that people developing drugs are.
This does not happen at present, which creates a huge
obstacle to generating high levels of evidence for these
tests. In fact, the Institute of Medicine addressed some
of the issues surrounding development of omics-based
tests [7]. Although this report was not specific to cancer
biomarker tests, it laid out a roadmap for investigators
to follow, ranging from discovery to test development to
demonstration of clinical utility.
Another important issue is how investigators report
tumor biomarker tests. The hallmark of the scientific
method is reproducibility, yet often for may published re-
ports of putative tumor biomarker tests it is very difficult to
determine the fundamental components of the research
methodology. In this regard, there have been several efforts
to standardize reporting criteria for pre-analytical, analytical
and clinical research strategies in these reports [8].
My second vision for the future is the next-generation
sequencing approach. This is the future of oncology, and
we are really looking forward to that. The third area for
the future of personalized oncology, I think, is not so
much a scientific revolution as it is a sociologic revolu-
tion, and that is the issue of being able to look at so-
called ‘big data’. With the advent of the use of electronic
medical records in many medical practices around the
US, we are going to have the ability to potentially review
millions of patients’ outcomes in the future and apply
the lessons we have learned from previous retrospective
analyses of how patients do when they are treated invarious ways. I hope that such approaches will remain
complementary to clinical trials, so that we can generate
prospective data from clinical trials but also do much
better comparative effectiveness research by having access
to huge databases.
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Stroke genetics: understanding disease and
prospects for personalized medicine
Hugh S Markus
It is still very early days in the genetics of stroke, but
recent studies from genome-wide association studies
(GWAS) are telling us some quite interesting things
about stroke [9]. First of all, they are telling us that dif-
ferent types of stroke, or different stroke mechanisms,
have quite different genetic backgrounds or architec-
ture. For example, the genes involved in large artery
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seem to be quite different from the genes involved in
stroke associated with cardioembolism - blood clots
coming from the heart. The results from GWAS are in-
creasing our understanding of the pathophysiology of
stroke. This may have important implications outside
genetics. For example, it suggests that we may need to
tailor our stroke treatments rather more towards dif-
ferent types of stroke than we do currently.
GWAS results are also beginning to tell us about
new pathways that may be involved in causing stroke.
Perhaps the most exciting one so far is a gene called
histone deacetylase 9 (HDAC9), which appears to be
associated with large artery – or atherosclerotic – stroke.
This may give us a new way of understanding the cause of
this type of stroke, which could potentially be targeted
with different treatment approaches. But this is a little way
off at the moment.
The field of stroke genetics is not as advanced as other
areas of medicine, for example oncology, in terms of
personalized risk prediction and therapy for a number of
reasons. First of all, the genes involved in stroke risk all
contribute just a small amount of increased risk. Unlike
some of the cancer genes, where a particular genetic
mutation substantially increases the risk of developing
a certain type of cancer, in stroke it appears likely that
there are lots and lots of different genes that are all
contributing, presumably, a small amount of risk.
Therefore, if you just look at one of these variants, it is
not going to give you the same sort of information as
you would obtain from perhaps looking at a cancer
gene. Another reason is that we have been quite late in
doing GWAS genetic studies in stroke and we are only
just beginning to scratch the surface. Many other diseases
have been looking at genetics with the GWAS approach
for rather longer, with much larger sample sizes. It may
well be that we can predict stroke risk in the future but at
the moment, because each of the identified genes only
contributes a very small amount of risk, we are still unable
to explain many of the genetic risk factors. Therefore,
looking at just a few genes, when there are many we do
not understand or have not yet discovered, is only going
to contribute a limited amount to overall risk.
The outlook for stroke prediction
In the future, genetics could be used to tailor treatment
for the individual patient in a number of possible ways.
One approach is in looking at pharmacogenomics. This
is where people respond differently to treatments ac-
cording to their genetic makeup. Tailored treatment is
already applied with drugs such as the anti-platelet
agent clopidogrel, which is frequently used to reduce
recurrent stroke, and warfarin, an anticoagulant that is
often used to prevent recurrent stroke in patients with,for example, atrial fibrillation. For both of these treat-
ments, there are genetic variants that determine how
the body breaks down the drug and therefore what sort
of dose of the drug you are going to need or, in the case
of clopidogrel, whether you are likely to respond well
to the drug or not. Therefore, there is already exciting
data that suggest you can look at these genetic variants
to tailor doses to individual people.
There has been considerable debate about how useful
these genetic tests are, particularly in the US where
there were recommendations, for example, that one
should test for clopidogrel sensitivity before giving clo-
pidogrel. What we really need to know is whether
adopting a program where you test individual patients’
genes and use it to guide therapy actually results in im-
proved outcome for patients. This still has to be proven.
In the UK, pharmacogenomics tools are not being used
very widely at the moment. Whether pharmacogenom-
ics actually has a major impact on outcome and allows
us to reduce recurrent stroke risk is currently being
determined in clinical trials. If such trials show they
really do predict outcome then pharmacogenomics may
be used more widely.
Another important question is whether we can predict
overall stroke risk in individual people. Because we only
know a few of the genes that are contributing to overall
genetic risk, this is a little way off. When many more
genetic studies with larger sample sizes have been car-
ried out and we can explain more of the overall genetic
risk, it may well be that we can start predicting risk in
individual people. The question then is whether we can
predict usefully more risk than we can with conven-
tional cardiovascular risk factors. For example, we know
that high blood pressure, smoking and having high chol-
esterol are linked to an increased risk of stroke. The
question is, can genetics predict more risk than these
factors, and how useful is it? We will only be able to an-
swer this when we have discovered more of the overall
genetic component for stroke.
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Diabetes management: targeting the right
treatment to the right patient
R David Leslie
Diabetes management is becoming more tailored to-
wards the individual patient in terms of the treatment
that is available and what that treatment does for the
patient. Twenty years ago, there were a very limited
number of drugs available for patient care. That is, we
had insulin, sulfonylureas and diguanylates. Our ap-
proach to the management of patient care was entirely
focused around the prevention of complications. We
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form of therapy, which was usually with one or other
of those drugs, and we always gave those drugs in the
context of trying to prevent progression of complica-
tions by reducing blood glucose. Diabetes management
employed a very glucose-centric approach in the past.
The number of drugs available to us has now increased
substantially and, as a result, the approaches to therapy
have become more diverse; we now have more options
in terms of drug therapy. Also, drug therapy available
previously was rather non-specific; everyone was given
the same treatment. However, we are now beginning to
identify sub-groups of people with diabetes in which in-
dividuals are more responsive to some of these agents,
or for which these agents are more suitable. We still,
unfortunately, are constrained by our approach, which
is the prevention of complications, but we have expanded
our horizons so that while before we had a glucose-centric
approach, now we focus not only on glucose but also
on smoking, hypertension, high blood cholesterol and
exercise [10].
The guidelines for managing diabetes have evolved in
recent years, and there are arguments for adopting
patient-tailored rather than guideline-led treatmentstrategies [11]. A guideline approach is very convenient
for someone who is not an expert because it gives,
quite literally, a guideline as to which direction you might
go and what drugs you might use. Professionals who are
experts in that field should not require a guideline. They
would know the condition and the person in front of
them - that is the very nature of a professional interaction.
The problem is that many guidelines are taken as tablets or
commandments; with the overwhelming number of cases
of diabetes, non-experts deal with cases in which guide-
lines are probably quite valuable to them because it gives
them a broad-brush approach to the condition, without
being able to modify or refine their management policy
[12]. Another problem is that there is a substantial lag be-
tween where we are as specialists and where the guidelines
are, so inevitably there will be positions taken by special-
ists that the people who produce guidelines are not going
to have had time to illustrate. We have this problem with
books. I have just published a text book, but I am sort of
wondering whether I should be producing any more be-
cause by the time you get round to publishing - inevitably
it has a two-year gestation, rather like a guideline - things
have changed. You started with one form of therapy and
you have moved on to another.
Currently, most diabetes drugs address insulin secretion;
very few address insulin sensitivity. This is a broad area
where we might be able to target people who have a
particularly severe problem with insulin sensitivity, where
their requirement for drugs is distinct from those whose
predominant problem is its secretion. We already know
that patients with adult-onset autoimmune diabetes who
do not require insulin initially seem to do badly with
sulfonylureas, yet sulfonylureas would be considered
to be the second line of treatment. Certainly all the
guidelines say as much. By way of contrast, there is an-
other type of diabetes associated with a genetic mutation,
maturity-onset diabetes of the young, in which sulfonyl-
urea is particularly prone to causing hypoglycemia, and it
is therefore necessary to give these patients a slightly
different agent. However, there is a really rare condition
where the potassium channel of the beta cell has a mu-
tation that can be circumvented by sulfonylureas [11].
These are all examples of how our understanding of the
pathophysiology and the genetics of the disease can be
applied to target the appropriate treatment. Now, there is
an additional issue with side effects: the more drugs you
use, the more likely you are to get side effects [10,13,14].
A lot of our patients get side effects. Of course, the more
drugs you have available, the greater the number of op-
tions. So if you have a particular side effect in a particular
individual - or a risk of a side effect - then it may be that
you will look at a different drug for that individual [12,15].
In addition to there being more drugs available, there
have also been changes in the targets that we have. For
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ent targets for blood glucose compared with someone
who is 20. This is because the person who is 80 is at
high risk of macrovascular complications, whereas the
person who is 20 is at risk of both macrovascular and
microvascular complications [11,15,16]. This is another
example of personalized medicine. Because we have dif-
ferent therapies and different targets for therapies and
different approaches to therapies, so we will start seeing
a more focused approach in the physicians who are un-
derstanding and treating the disease.
Prospects for diabetes management
Looking forwards, I think the future of this field is very
substantial - and when I say this field, I mean the concept
of personalized medicine in general as compared with our
current guidelines. I think this extends far beyond diabetes
into a wide range of medical conditions. The two key
questions are: what are we going to use and why are we
going to use it? In terms of what we are going to use, as
we understand more about the heterogeneity of the dis-
ease, then we will be able to target the increasing num-
ber of drugs that are available to a particular individual
with a particular condition [10,17,18]. As we find more
about the genetics that underline the process of diabetes,
and as we identify more how one person with diabetes
differs from another, so we will be able to identify drugs
that are of specific value in that individual.
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Innovations and legislations in mobile health
apps: are they suitable for all?
Eric J Topol
The field of mobile health has advanced very rapidly in
the last few years. If you look back at the first 10 years
of this century, these little devices - starting with iPods
and quickly migrating through smart phones, e-readers
and tablets - have changed our world. That was in terms
of day-to-day living, but now we are starting to see
the same thing in medicine; these little mobile devices
having a profound and really a transformative effect
on the future of healthcare [19].
The smartphone will become the hub of future medicine,
because it has a pluripotent impact. For one, it can be the
conduit of sensor information. Smartphones can be used to
measure blood pressure, glucose, heart rhythm and brain
waves; the list is almost endless. In addition to biosensors,
we also have the ability to change a mobile phone into a
scanner - an otoscope, ophthalmoscope, microscope or
any kind of scope - and in fact there are even little ultra-
sound devices that can function as a mobile phone. Theseare all examples of how mobile phones can be used as
medical sensors. Another way the smartphone can be used
in medicine is by functioning as a laboratory on a chip,
which is capable of doing almost any common laboratory
assay. These include tests for kidney function, liver func-
tion, thyroid function, blood thinning international nor-
malized ratio, potassium, and many more. These are just a
few ways that smartphones can be used for collecting data
and capturing information for a particular individual, to
shape that person’s care.
An important consideration in the advancing field of
mobile health is safety and regulation of smartphone apps.
The US Food and Drugs Administration recently released
a statement on this issue to say that most smartphone
apps do not require their oversight. The only ones requir-
ing regulation are those that make critical measurements
such as blood glucose, blood pressure and heart rhythm -
these are important devices. For example, an error in glu-
cose measurement could result in a patient taking a lot of
insulin, leading to coma, seizures or even death. Devices
that make critical measurements are not just apps, they
are also add-ons to the phone; they involve hardware and
there has to be some demonstration that accuracy has
been fulfilled. I think it is vital that we have an independ-
ent agency, a regulatory body that can assure that the
things being measured are being done so in a highly rigor-
ous, accurate way.
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must determine whether they are suitable for people with-
out medical training to use. Smartphones are immensely
popular; there are more cell phones in the world - by a
great margin - than the number of people, toilets and
toothbrushes. In the present day, a large proportion of
people who own a cell phone have a smartphone. There-
fore, we would like apps that are used for medical tracking
to be very consumer-oriented with a friendly user interface.
Of course some of them have that, such as those that meas-
ure blood pressure and glucose. Some mobile medical de-
vices are really showing that making critical measurements
can be achieved without any medical training, and that is of
course the path that mobile health needs to go on.
There are a few potential risks associated with using
mobile apps in healthcare that are important to mention.
Firstly, lack of accuracy is a key concern. For example, if
a mobile device was accurate and then started to lose its
calibration, this would be an important safety issue.
Many apps do not require subsequent calibration after
coming out of the factory. However, some do require
monitoring, and in these cases there would be specific
recommendations about whether there is any potential
for drift. For example, if a device functions as a glucose
sensor, it is necessary to re-check the calibration with a
conventional finger stick at x number of days to ensure
that there has been no drift.
A second concern would be security of the data; po-
tential problems could be escapes or re-identification of
data that are supposed to be kept de-identified. This
issue has to be addressed because anything that is digi-
tized can be hacked into or breached, so data privacy is
a concern. The third level of risk is inducing severe anx-
iety. That is, it is very difficult for some people to have
their own data continuously displayed on their device.
People who would worry about their data would tend to
be highly anxious anyway, and this continuous monitor-
ing would create another cause of anxiety at a high level.
It is important to establish which patients are not suit-
able for this, and how we can reduce this type of anxiety.
As a doctor, it is important to realize that mobile health
is not good for all people. You have to figure out which
individuals will benefit from continuous monitoring of
their health.
The big question about using smartphones in medicine
is whether they can change behavior and encourage
people to live healthier lifestyles; that is the hardest thing
to do. However, in the era of mobile health, we have
real-time, continuous data, passively being captured.
What remains to be seen is whether or not that will in-
deed push people to become more healthy in their life-
style. There is a great deal of hope for this approach,
and there are ways that people can be incentivized to be
more healthy; this can be done through smartphonegames and managed competition. There are all sorts of
ways in which having one’s own data could be a stimulus
to living a better lifestyle and, ideally, preventing the de-
velopment of a chronic condition.
The promise of mobile health
I think this is the most exciting time in the history of medi-
cine and it is because of mobile health. I think that, just as
medicine is moving into crisis mode in economic terms,
fortunately at the same time the area of mobile health is
blossoming, exploding with innovation. It has a lot of
promise for lowering costs for the first time, which has
never really been the case with new technology in medicine.
Because mobile health is consumer-based - it is a consumer
cell phone, and people have access to their own data - it is
particularly enthralling for me to see this shift away from
the doctor-dominated world of medicine to a much better
parity and symmetry of information; the flow of informa-
tion directly to the patient and then the guidance from the
physician. I am really impressed with how far this field has
come already in such a short time and where it can go. In
the era of mobile medical apps, the goal is ultimately to re-
duce the number of times patients have to visit the doctor.
So much of this information can be acquired anywhere at
any time, so in the future it may not be necessary to go to
the doctor to get a blood pressure check or a heart rhythm
check. Many measurements could be carried out by oneself,
at people’s own convenience, and much more data could be
collected than ever before.
The hope is that mobile health will lead to a marked
reduction in resource consumption and emergency
room use, and ultimately there will be fewer people in
the hospital because they can have their vital signs and
critical measurements assessed anywhere. We hope that
the only people in hospital will be those who are acutely
ill in the intensive care unit, or those who are there for a
special procedure or operation. But mostly, the majority
of people will be at their home, which is much safer
from the standpoint of infection and medication errors,
and much cheaper. What is more, patients will be able
to sleep in their own bed, while previously it was neces-
sary to stay in hospital. I envision mobile health will give
rise to the end of the hospital as we know it today, and
the end of office visits as we know them today; these will
not end entirely, but will have a radical re-booting.
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